top of page

KLUS Pharma to attend 2023 AACR Annual Meeting

KLUS Pharma will attend the 2023 AACR Annual Meeting held live in Orlando, Florida from April 14-19.

KLUS Pharma is the US subsidiary of Kelun-Biotech, a mid-sized innovative biopharma company based in Chengdu, China. Kelun-Biotech is advancing a broad pipeline of small molecules, monoclonal antibodies, and antibody-drug conjugates (ADCs) for the treatment of cancer. With multiple programs in late stage clinical trials, such as HER2 ADC to treat HER2+/HR- metastatic breast cancer, and TROP2 ADC for the treatment of a wide range of solid tumors, Kelun-Biotech is aiming to address the unmet needs of cancer patients by bringing novel, safer, and affordable medicines to market. In this current competitive landscape, we believe it is more important than ever to work with potential collaborators to achieve meaningful advances in this field, including exploring combination therapy synergies, leveraging regional/global clinical trial resources, and striving to improve existing discovery and development capabilities.

Therefore, we are looking forward to meeting potential collaborators and exploring all the latest ground-breaking research to be presented at AACR Annual Meeting, which has served as a premier event for scientists, clinicians, industry, and patients to meet and share knowledge for advancing the treatment of cancer.

Business Development Team

Monday, April 10, 2023

bottom of page